Medication info
Rostel Plus Tablet 80/5/10 Milligrams

Rostel Plus Tablet 80/5/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Samchundang Pharm Co., Ltd.
Appearance
Oval bilayer tablet consisting of a white layer and a light blue layer
Packaging
For domestic use - 30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202302008 · Approved 2023.06.29 · Insurance code 651206070

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting telmisartan/amlodipine combination therapy, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, based on LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Ingredients

Manufacturer
Samchundang Pharm Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • mixed hyperlipidemia
  • familial homozygous hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with hypertension whose blood pressure is not well controlled with telmisartan and amlodipine monotherapy, and should only be used when rosuvastatin needs to be administered simultaneously. The telmisartan/amlodipine combination effectively controls essential hypertension, while rosuvastatin is used as an adjunct to diet in patients with hypercholesterolemia and dyslipidemia not controlled by diet and exercise. It also helps delay the progression of atherosclerosis and reduce the risk of cardiovascular disease. Particularly, in high-risk patients aged midlife and above, it plays a significant role in lowering the risk of stroke, myocardial infarction, and arterial revascularization procedures. This medication effectively manages hypertension and dyslipidemia, improving cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting telmisartan/amlodipine combination therapy, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, based on LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Precautions

This medication should not be used in pregnant women. Particularly in early pregnancy, it can cause serious harm to the fetus, so if pregnancy is confirmed, it should be discontinued immediately. This medication should not be administered to patients with allergies to the ingredients or similar medications, patients with hereditary angioedema or a related history. It should also not be used in patients with severe liver or kidney dysfunction, severe heart valve disease, or in shock. Before taking this medication, it is essential to consult with a doctor, especially for elderly patients, those with low blood pressure, hyperkalemia, or liver or kidney issues who require extra caution. During treatment, if muscle pain, weakness, or severe fatigue occurs, notify a doctor immediately, and muscle damage can be checked through blood testing. If liver function abnormalities are suspected, discontinue use and consult a healthcare professional. Since interactions may occur with other medications, be sure to inform your doctor or pharmacist of any other medicines you are taking. This medication is also not recommended for breastfeeding women; if taken, breastfeeding should be discontinued. Safety and efficacy have not been adequately established for children, so it is preferable to avoid use in pediatric patients. In case of overdose, symptoms such as low blood pressure, dizziness, and kidney dysfunction may occur, thus timely medical treatment should be sought. This medication should be stored away from direct sunlight and kept out of the reach of children, and it is advisable not to transfer it to another container.

Side effects

Peripheral edema, dyspepsia, frequent bowel movements, diabetes mellitus, dizziness, dry vesicular sound, urticaria, unstable angina, onychomycosis, lumbar spinal canal stenosis, ear discharge, vertigo, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified intestinal diseases, benign gastrointestinal tumors, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, edema, autonomic nervous system abnormalities (erectile dysfunction, increased sweating, flushing), allergies, fever, leg pain, lethargy, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory abnormalities, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal diseases, gout, hypercholesterolemia, anxiety, depression, irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, rhinitis, dyspnea, epistaxis, dermatitis, rash, eczema, pruritus, angioedema, erythema multiforme, erythematous rash, papular rash, frequent urination, cystitis, vasculitis, peripheral neuropathy, tremor, anorexia, dysphagia, pancreatitis, gingival hyperplasia, asthenia, burning sensation, rigidity, weight gain, weight loss, sexual dysfunction, insomnia, abnormal dreams, depersonalization, dyspnea, epistaxis, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, myalgia, myopathy, rhabdomyolysis, asthenia, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified intestinal diseases, benign gastrointestinal tumors, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, angioedema, thrombocytopenia, acute renal failure, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, hypotension, tachycardia, bradycardia, acute renal failure, hypotension, reflex tachycardia, severe hypotension, non-cardiogenic pulmonary edema, jaundice, elevated liver enzyme levels, gynecomastia, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, headache, dizziness, increased ALT, chest pain, cough, myalgia, increased CK, constipation, increased AST, asthenia, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, anorexia, abdominal distention, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a light-resistant container. Additionally, it should be stored at room temperature between 1 degree and 30 degrees Celsius, avoiding excessively hot or cold conditions.

Appearance and packaging

Appearance

Oval bilayer tablet consisting of a white layer and a light blue layer

Package unit

For domestic use - 30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.